Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT03202745

The Effect of Informative Letters on the Prescription and Receipt of Opioids

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Abdul Latif Jameel Poverty Action Lab · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

Inappropriate prescribing exposes patients to health risks and results in wasteful public expenditures. This study will evaluate an approach to fighting abusive prescription: sending letters to suspected potentially inappropriate prescribers warning them that they are outliers compared to their peers and have been flagged for review. The study will target high prescribers of opioids in the Schedule II controlled substances class. Two types of letters will be tested: one focusing on the health consequences of inappropriate prescribing for patients, and the other focusing on the consequences for prescribers including e.g. potential administrative actions. Using claims data, the investigators will assess the effect of the letters on prescribing of opioids, receipt of opioids by patients, substitution behavior by prescribers and patients, and health outcomes of patients.

Conditions

Interventions

TypeNameDescription
OTHERPatient Consequences LetterThis letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
OTHERPrescriber Consequences LetterThis letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.

Timeline

Start date
2017-01-01
Primary completion
2018-01-01
Completion
2019-01-01
First posted
2017-06-29
Last updated
2021-08-12

Source: ClinicalTrials.gov record NCT03202745. Inclusion in this directory is not an endorsement.